Merck & Co., Inc.  

(Public, NYSE:MRK)   Watch this stock  
Find more results for MRK
58.82
+0.03 (0.05%)
Jul 22 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 58.55 - 59.08
52 week 45.69 - 60.07
Open 58.99
Vol / Avg. 0.00/9.71M
Mkt cap 162.90B
P/E 35.98
Div/yield 0.46/3.13
EPS 1.63
Shares 2.77B
Beta 0.66
Inst. own 75%
Jul 29, 2016
Q2 2016 Merck & Co Inc Earnings Release - 9:30AM EDT - Add to calendar
Jul 29, 2016
Q2 2016 Merck & Co Inc Earnings Call - 8:00AM EDT - Add to calendar
Jun 6, 2016
Merck & Co Inc Investor Briefing at 2016 ASCO Annual Meeting
May 25, 2016
Merck & Co Inc Annual Shareholders Meeting (Estimated)
May 25, 2016
Merck & Co Inc at UBS Global Healthcare Conference
May 24, 2016
Merck & Co Inc Annual Shareholders Meeting
May 5, 2016
Merck & Co Inc at Deutsche Bank Health Care Conference
May 5, 2016
Q1 2016 Merck & Co Inc Earnings Release
May 5, 2016
Q1 2016 Merck & Co Inc Earnings Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '16) 2015
Net profit margin 12.13% 11.29%
Operating margin 17.96% 13.97%
EBITD margin - 51.60%
Return on average assets 4.52% 4.46%
Return on average equity 10.20% 9.52%
Employees 68,000 -
CDP Score - 99 B

Address

2000 Galloping Hill Rd
KENILWORTH, NJ 07033-1310
United States - Map
+1-908-7404000 (Phone)
+1-908-4231987 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
About Company - Wikipedia

Description

Merck & Co., Inc. is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company's Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed healthcare providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Company's animal health products are sold to veterinarians, distributors and animal producers.

Officers and directors

Kenneth C. Frazier Chairman of the Board, President, Chief Executive Officer
Age: 61
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Robert M. Davis Chief Financial Officer, Executive Vice President
Age: 49
Bio & Compensation  - Reuters
Clark Golestani Executive Vice President, Chief Information Officer
Age: 49
Bio & Compensation  - Reuters
Michael J. Holston Executive Vice President, General Counsel
Age: 53
Bio & Compensation  - Reuters
Mirian M. Graddick-Weir Executive Vice President - Human Resources
Age: 61
Bio & Compensation  - Reuters
Sanat Chattopadhyay Executive Vice President and President - Merck Manufacturing Division
Bio & Compensation  - Reuters
Richard R. DeLuca Jr. Executive Vice President, President - Merck Animal Health
Age: 53
Bio & Compensation  - Reuters
Julie Louise Gerberding M.D. Executive Vice President - Strategic Communications, Global Public Policy & Population Health
Age: 60
Bio & Compensation  - Reuters
Roger M. Perlmutter M.D. Ph.D. Executive Vice President, President - Merck Research Laboratories
Age: 64
Bio & Compensation  - Reuters
Michael Rosenblatt M.D. Executive Vice President, Chief Medical Officer
Age: 68
Bio & Compensation  - Reuters